LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Merck & Company today. The company’s shares opened today at $83.96. Elevate Your Investing Strategy: T ...